ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Biogen’s patent on Tecfidera upheld

by Ann M. Thayer
March 27, 2017 | APPEARED IN VOLUME 95, ISSUE 13

The U.S. Patent & Trademark Office’s Patent Trial & Appeal Board has ruled in Biogen’s favor regarding a patent on the company’s multiple sclerosis drug Tecfidera, which had sales last year of $4 billion. Activist investor J. Kyle Bass had sought to have the dosage-related patent invalidated to enable the emergence of generic versions. The same patent is also the subject of an interference proceeding with a patent owned by Forward Pharma on the drug’s active ingredient, dimethyl fumarate. In January, Biogen paid Forward, a Danish biotech firm, $1.25 billion to defer royalty claims.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment